Immunomodulation does not alter histology in resected Crohn's disease

Techniques in Coloproctology

Volumn 13, Issue 4, 2009, Pages 295-300

  Frizelle, F A ^a,c   Ing, A ^a   Gearry, R B ^a,c   Whitehead, M ^a   Faragher, I G ^b   Dobbs, B ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b Western Hospital   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; AGED; ARTICLE; COLON DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FISTULA; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEUM DISEASE; IMMUNOMODULATION; INFLAMMATION; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERTROPHY; PHENOTYPE; RETROSPECTIVE STUDY; STRICTURING;

ADULT; ANTI-INFLAMMATORY AGENTS; COLON; COMBINED MODALITY THERAPY; CROHN DISEASE; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MALE; PHENOTYPE; RETROSPECTIVE STUDIES;

EID: 77949917037     PISSN: 11236337     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10151-009-0538-7     Document Type: Article

References (33)

1. RB Gearry A Richardson CM Frampton, et al. 2006 High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study Inflamm Bowel Dis 12 936 943 10.1097/01.mib.0000231572.88806.b9 17012964 (Pubitemid 44498282)
2. DC Baumgart SR Carding 2007 Inflammatory bowel disease: cause and immunobiology Lancet 369 1627 1640 10.1016/S0140-6736(07)60750-8 1:CAS:528:DC%2BD2sXltF2qsrc%3D 17499605 (Pubitemid 46722636)
3. P Rutgeerts K Goboes M Peeters, et al. 1991 Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum Lancet 338 771 774 10.1016/0140-6736(91)90663-A 1:STN:280:DyaK38%2Fhs1Olsw%3D%3D 1681159
4. A Krishnan JR Korzenik 2002 Inflammatory bowel disease and environmental influences Gastroenterol Clin North Am 31 21 39 10.1016/S0889-8553(01)00003-6 12122733 (Pubitemid 34733031)
5. RJ Xavier DK Podolsky 2007 Unravelling the pathogenesis of inflammatory bowel disease Nature 448 427 434 10.1038/nature06005 1:CAS:528: DC%2BD2sXotFajurs%3D 17653185 (Pubitemid 47123518)
6. S Candy J Wright M Gerber G Adams M Gerig R Goodman 1995 A controlled double blind study of Azathioprine in the management of Crohn's disease Gut 37 674 678 10.1136/gut.37.5.674 1:CAS:528:DyaK28XktVWhsA%3D%3D 8549944
7. DH Present BI Korelitz N Wisch JL Glass DB Sachar BS Pasternack 1980 Treatment of Crohn's disease with 6-Mercaptopurine. A long-term, randomized, double-blind study N Engl J Med 302 981 987 1:STN:280:DyaL3c7msFelsw%3D%3D 6102739
8. BG Feagan J Rochon RN Fedorak, et al. 1995 Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 292 297 10.1056/NEJM199502023320503 1:STN:280:DyaK2M7hsFOitA%3D%3D 7816064
9. Alfadhli AA, McDonald JW, Feagan BG (2005) Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. CD003459
10. BG Feagan RN Fedorak EJ Irvine, et al. 2000 A comparison of Methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 1627 1632 10.1056/NEJM200006013422202 1:CAS:528:DC%2BD3cXktF2gsr4%3D 10833208 (Pubitemid 30341531)
11. DH Present P Rutgeerts S Targan, et al. 1999 Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1398 1405 10.1056/NEJM199905063401804 1:CAS:528:DyaK1MXjtF2mu74%3D 10228190 (Pubitemid 29205403)
12. BE Sands FH Anderson CN Bernstein, et al. 2004 Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 876 885 10.1056/NEJMoa030815 1:CAS:528:DC%2BD2cXhsFyitLo%3D 14985485 (Pubitemid 38252535)
13. SB Hanauer BG Feagan GR Lichtenstein, et al. 2002 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541 1549 10.1016/S0140-6736(02)08512-4 1:CAS:528:DC%2BD38Xkt1Gru70%3D 12047962 (Pubitemid 34621118)
14. J Cosnes I Nion-Larmurier L Beaugerie P Afchain E Tiret JP Gendre 2005 Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery Gut 54 237 241 10.1136/gut.2004.045294 1:STN:280:DC%2BD2M%2FitFSrsw%3D%3D 15647188 (Pubitemid 40139240)
15. G D'Haens K Geboes E Ponette F Penninckx P Rutgeerts 1997 Healing of severe recurrent ileitis with Azathioprine therapy in patients with Crohn's disease Gastroenterology 112 1475 1481 10.1016/S0016-5085(97)70027-1 9136824
16. G D'Haens S Van Deventer R Van Hogezand, et al. 1999 Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial Gastroenterology 116 1029 1034 10.1016/S0016-5085(99)70005-3 10220494 (Pubitemid 29203012)
17. EF Stange SP Travis S Vermeire, et al. 2006 European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis Gut 55 Suppl 1 11 15
18. G D'Haens K Geboes P Rutgeerts 1999 Endoscopic and histologic healing of Crohn's (ileo-) colitis with Azathioprine Gastrointest Endosc 50 667 671 10.1016/S0016-5107(99)80017-0 10536324 (Pubitemid 29518050)
19. K Geboes P Rutgeerts G Opdenakker, et al. 2005 Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease Curr Med Res Opin 21 1741 1754 10.1185/030079905X65457 1:CAS:528:DC%2BD28XnslM%3D 16307694 (Pubitemid 41667241)
20. ID Arnott D Watts S Ghosh 2002 Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 16 857 867 10.1046/j.1365-2036.2002.01242.x 1:CAS:528:DC%2BD38Xkt1Gksb4%3D 11966492 (Pubitemid 34461753)
21. M Allez M Lemann J Bonnet P Cattan R Jian R Modigliani 2002 Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy Am J Gastroenterol 97 947 953 12003431
22. G D'Haens 2004 Mucosal healing in pediatric Crohn's disease: the goal of medical treatment Inflamm Bowel Dis 10 479 480 10.1097/00054725-200407000-00024 15475761 (Pubitemid 39029195)
23. JA Tibble G Sigthorsson S Bridger MK Fagerhol I Bjarnason 2000 Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease Gastroenterology 119 15 22 10.1053/gast.2000.8523 1:STN:280:DC%2BD3czkvFCjuw%3D%3D 10889150
24. GR D'Haens AE Gasparaitis SB Hanauer 1995 Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease Gut 36 715 717 10.1136/gut.36.5.715 7797122
25. GT Ho P Chiam H Drummond J Loane ID Arnott J Satsangi 2006 The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort Aliment Pharmacol Ther 24 319 330 10.1111/j.1365-2036.2006. 02974.x 1:CAS:528:DC%2BD28Xosl2gtbk%3D 16842459 (Pubitemid 43972900)
26. PM Irving RB Gearry MP Sparrow PR Gibson 2007 Review article: appropriate use of corticosteroids in Crohn's disease Aliment Pharmacol Ther 26 313 329 1:CAS:528:DC%2BD2sXhtVSiu77I 17635367
27. I Tiede G Fritz S Strand, et al. 2003 CD28-dependent Rac1 activation is the molecular target of Azathioprine in primary human CD4+ T lymphocytes J Clin Invest 111 1133 1145 1:CAS:528:DC%2BD3sXjtFCrsrY%3D 12697733
28. DM Nathan JH Iser PR Gibson 2008 A single center experience of Methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration J Gastroenterol Hepatol 23 954 958 10.1111/j.1440-1746.2007.05006.x 1:CAS:528:DC%2BD1cXptFylsL0%3D 17559377
29. P Rutgeerts RH Diamond M Bala, et al. 2006 Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease Gastrointest Endosc 63 433 442 10.1016/j.gie.2005.08.011 16500392 Quiz 64 (Pubitemid 43261469)
30. P Rutgeerts BG Feagan GR Lichtenstein, et al. 2004 Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology 126 402 413 10.1053/j.gastro.2003.11.014 1:CAS:528: DC%2BD2cXhvV2rsbs%3D 14762776 (Pubitemid 38182297)
31. K Geboes I Dalle 2002 Influence of treatment on morphological features of mucosal inflammation Gut 50 Suppl 3 III37 III42 10.1136/gut.50.suppl-3.iii37 11953331
32. JY Mary R Modigliani 1989 Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID) Gut 30 983 989 10.1136/gut.30.7.983 1:STN:280:DyaL1MzjvFarug%3D%3D 2668130
33. P Gomes C du Boulay CL Smith G Holdstock 1986 Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease Gut 27 92 95 10.1136/gut.27.1.92 1:STN:280: DyaL287jslKktQ%3D%3D 3949241